Shanghai United Imaging Healthcare (688271) Q4 2024 earnings summary

Executive summary

• Revenue for 2024 was RMB 10,300.1 million, down 9.73% year-over-year.

• Net profit attributable to shareholders was RMB 1,261.9 million, a 36.08% decrease year-over-year.

• R&D investment increased, with a focus on technological innovation and new product launches.

• Overseas revenue grew rapidly, offsetting some domestic market contraction.

Financial highlights

• Operating profit fell 36.20% year-over-year to RMB 1,366.4 million.

• Net profit excluding non-recurring items dropped 39.32% year-over-year.

• Basic EPS was RMB 1.54, down 35.83% year-over-year.

• Total assets increased 10.65% to RMB 28,035.7 million at year-end.

• Shareholders’ equity rose 5.50% to RMB 19,903.2 million.

Outlook and guidance

• Anticipates rapid performance improvement as domestic policies stabilize and market recovers.

• New innovative and differentiated products expected to drive future growth.

• Overseas business expansion and partnerships with top international medical institutions to continue.

• Ongoing supply chain optimization and cost control measures to enhance profitability.